Verve Therapeutics Inc
NASDAQ:VERV

Watchlist Manager
Verve Therapeutics Inc Logo
Verve Therapeutics Inc
NASDAQ:VERV
Watchlist
Price: 11.13 USD Market Closed
Market Cap: 992.1m USD

Operating Margin
Verve Therapeutics Inc

-349.7%
Current
-3 346%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-349.7%
=
Operating Profit
-208.5m
/
Revenue
59.6m

Operating Margin Across Competitors

No Stocks Found

Verve Therapeutics Inc
Glance View

Market Cap
988.3m USD
Industry
Biotechnology

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. The company is headquartered in Cambridge, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2021-06-17. The firm is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The company is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The firm's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The firm's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.

VERV Intrinsic Value
2.15 USD
Overvaluation 81%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-349.7%
=
Operating Profit
-208.5m
/
Revenue
59.6m
What is the Operating Margin of Verve Therapeutics Inc?

Based on Verve Therapeutics Inc's most recent financial statements, the company has Operating Margin of -349.7%.

Back to Top